Rainbow Seed Fund News

British molecular diagnostics company Cytox plans to make a molecular test for the early-stage diagnosis of Alzheimer’s disease available in the US by year end. The Oxford-based firm is also in discussions with multiple pharmaceutical and biotechnology companies that wish to use its test, which is run on a custom Affymetrix microarray, to select patients […]

read more

— Early-stage venture fund key in bridging gap between UK research and commercialisation — Fund aims to turn UK scientific ‘world’s first’ ambitions into market-leading companies Rainbow Seed Fund, an early-stage venture capital fund focused on promising technologies developed at the UK’s largest publicly-funded research facilities and campuses, today announces that the fund have now […]

read more

CellCentric is developing first in class drug compounds against a key regulator of cancer. P300/CBP are twin (paralogue) histone acetyltransferase proteins, that act as transcriptional co-factors. When inhibited they cause the down regulation of the androgen receptor (AR) and its variants. It also decreases c-Myc, another key cancer driver. CellCentric has been focusing the use […]

read more

1 2 3 4 19